Table 1.
Median, range and statistical inferences of the differences in plasma concentrations of amitriptyline and metabolites in the CYP2D6 extensive (n = 17) and poor metabolizers (n = 4) among 21 Faroese patients in treatment with amitriptyline
| EM | PM | Geometric mean ratio (PM/EM) (95% CI) | P-value | |
|---|---|---|---|---|
| CAT+NT/dose* | 4.4 (1.1–18.2) | 6.5 (5.7–10.6) | 1.69 (0.75–3.82) | 0.191 |
| NT/dose* | 1.49 (0.41–5.26) | 3.42 (2.22–4.87) | 2.21 (0.94–5.20) | 0.066 |
| (E)-10-OH-NT/dose* | 3.59 (1.61–8.71) | 1.00 (0.95–1.94) | 0.32 (0.19–0.53) | 0.0005 |
| NT/(E)-10-OH-NT | 0.34 (0.22–1.05) | 3.07 (1.49–5.10) | 7.04 (3.92–12.63) | 0.0005 |
| AT/dose*† | 2.4 (1.20–14.32) | 3.89 (1.73–5.74) | 1.28 (0.54–3.01) | 0.556 |
| (E)-10-OH-AT/dose*‡ | 0.76 (0.25–1.65) | 0.41 (0.16–0.71) | 0.56 (0.25–1.22) | 0.136 |
| AT/(E)-10-OH-AT§ | 4.0 (1.7–13.7) | 10.7 (5.8–14.1) | 2.16 (1.06–4.42) | 0.036 |
*
nm mg−1 day−1.
†
EM (n = 16), PM (n = 4).
‡
EM (n = 17), PM (n = 3).
§
EM (n = 16), PM (n = 3). Different n's are used as AT or metabolites were not quantifiable in all samples. EM, Extensive metabolizer; PM, poor metabolizer; NT, nortripyline; AT, amitriptyline.